NCT00990938View on ClinicalTrials.gov

Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

January 31, 2011

Conditions
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Interventions
DRUG

IMO-2125

IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.

DRUG

Saline

Subcutaneous injection once per week for four weeks

Trial Locations (1)

35000

Rennes

Sponsors
All Listed Sponsors
lead

Idera Pharmaceuticals, Inc.

INDUSTRY